Skip to main content
Top
Published in: Arthritis Research & Therapy 2/2008

01-04-2008 | Editorial

Rheumatologists, take heart! We may be doing something right

Author: Ronald F van Vollenhoven

Published in: Arthritis Research & Therapy | Issue 2/2008

Login to get access

Abstract

In the present issue of Arthritis Research & Therapy data are presented suggesting that antirheumatic therapies decrease the risk of cardiovascular disease in patients with rheumatoid arthritis. The QUEST-RA group, a large international collaboration, analyzed data on 4,363 patients in a cross-sectional manner. Traditional risk factors were all significantly associated with cardiovascular events, and the presence of extraarticular disease significantly increased the risk, confirming a previous publication. The most interesting analysis in this study suggests that effective antirheumatic treatment, with traditional disease-modifying antirheumatic drugs (DMARDs), glucocorticoids, or anti-TNF biologics, reduces the risk of cardiovascular disease in rheumatoid arthritis. Some methodological issues are discussed, however, and confirmatory studies are suggested.
Literature
1.
go back to reference Naranjo A, Sokka T, Descalzo MA, Calvo-Alen J, Horslev-Petersen K, Luukkainen R, Combe B, Burmester GR, Devlin J, Ferraccioli G, Morelli A, Hoekstra M, Majdan M, Sadkiewicz S, Belmonte M, Holmqvist AC, Choy E, Tunc R, Dimic A, Bergman MJ, Toloza S, Pincus T: Cardiovascular disease in patients with rheumatoid arthritis. Results from the QUEST-RA study. Arthritis Res Ther. 2008, 10: R30-10.1186/ar2383.PubMedCentralCrossRefPubMed Naranjo A, Sokka T, Descalzo MA, Calvo-Alen J, Horslev-Petersen K, Luukkainen R, Combe B, Burmester GR, Devlin J, Ferraccioli G, Morelli A, Hoekstra M, Majdan M, Sadkiewicz S, Belmonte M, Holmqvist AC, Choy E, Tunc R, Dimic A, Bergman MJ, Toloza S, Pincus T: Cardiovascular disease in patients with rheumatoid arthritis. Results from the QUEST-RA study. Arthritis Res Ther. 2008, 10: R30-10.1186/ar2383.PubMedCentralCrossRefPubMed
2.
go back to reference Turesson C, McClelland RL, Christianson TJ, Matteson EL: Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis. 2007, 66: 70-75. 10.1136/ard.2006.052506.PubMedCentralCrossRefPubMed Turesson C, McClelland RL, Christianson TJ, Matteson EL: Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis. 2007, 66: 70-75. 10.1136/ard.2006.052506.PubMedCentralCrossRefPubMed
3.
go back to reference Wijnands MJ, van't Hof MA, van Leeuwen MA, van Rijswijk MH, van de Putte LB, van Riel PL: Long-term second-line treatment: a prospective drug survival study. Br J Rheumatol. 1992, 31: 253-258. 10.1093/rheumatology/31.4.253.CrossRefPubMed Wijnands MJ, van't Hof MA, van Leeuwen MA, van Rijswijk MH, van de Putte LB, van Riel PL: Long-term second-line treatment: a prospective drug survival study. Br J Rheumatol. 1992, 31: 253-258. 10.1093/rheumatology/31.4.253.CrossRefPubMed
4.
go back to reference Wolfe F: The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol. 1995, 9: 619-632. 10.1016/S0950-3579(05)80305-X.CrossRefPubMed Wolfe F: The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol. 1995, 9: 619-632. 10.1016/S0950-3579(05)80305-X.CrossRefPubMed
5.
go back to reference Wick MC, Lindblad S, Weiss RJ, Klareskog L, van Vollenhoven RF: Estimated prediagnosis radiological progression: an important tool for studying the effects of early disease modifying antirheumatic drug treatment in rheumatoid arthritis. Ann Rheum Dis. 2005, 64: 134-137. 10.1136/ard.2004.020636.PubMedCentralCrossRefPubMed Wick MC, Lindblad S, Weiss RJ, Klareskog L, van Vollenhoven RF: Estimated prediagnosis radiological progression: an important tool for studying the effects of early disease modifying antirheumatic drug treatment in rheumatoid arthritis. Ann Rheum Dis. 2005, 64: 134-137. 10.1136/ard.2004.020636.PubMedCentralCrossRefPubMed
6.
go back to reference Hansson GK, Robertson AK, Söderberg-Nauclér C: Inflammation and atherosclerosis. Annu Rev Pathol. 2006, 1: 297-329. 10.1146/annurev.pathol.1.110304.100100.CrossRefPubMed Hansson GK, Robertson AK, Söderberg-Nauclér C: Inflammation and atherosclerosis. Annu Rev Pathol. 2006, 1: 297-329. 10.1146/annurev.pathol.1.110304.100100.CrossRefPubMed
7.
go back to reference van der Wal AC, Becker AE: Atherosclerotic plaque rupture-pathologic basis of plaque stability and instability. Cardiovasc Res. 1999, 41: 334-344. 10.1016/S0008-6363(98)00276-4.CrossRefPubMed van der Wal AC, Becker AE: Atherosclerotic plaque rupture-pathologic basis of plaque stability and instability. Cardiovasc Res. 1999, 41: 334-344. 10.1016/S0008-6363(98)00276-4.CrossRefPubMed
Metadata
Title
Rheumatologists, take heart! We may be doing something right
Author
Ronald F van Vollenhoven
Publication date
01-04-2008
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 2/2008
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2364

Other articles of this Issue 2/2008

Arthritis Research & Therapy 2/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine